Healthcare provider profile · identity verified

Edina Sehovic Torlak, MD

Internal Medicine · CARMICHAEL, CA · NPI 1780751321

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	539	220
Levothyroxine Sodium	Levothyroxine Sodium	431	155
Amlodipine Besylate	Amlodipine Besylate	353	130
Losartan Potassium	Losartan Potassium	229	86
Lisinopril	Lisinopril	201	81
Omeprazole	Omeprazole	150	59
Metoprolol Succinate	Metoprolol Succinate	141	52
Hydrochlorothiazide	Hydrochlorothiazide	131	54
Metformin Hcl	Metformin Hcl	130	61
Pantoprazole Sodium	Pantoprazole Sodium	122	46
Gabapentin	Gabapentin	121	41
Furosemide	Furosemide	120	37
Fluticasone Propionate	Fluticasone Propionate	116	48
Metoprolol Tartrate	Metoprolol Tartrate	113	47
Sertraline Hcl	Sertraline Hcl	113	31
Potassium Chloride	Potassium Chloride	106	37
Rosuvastatin Calcium	Rosuvastatin Calcium	97	32
Montelukast Sodium	Montelukast Sodium	89	31
Trazodone Hcl	Trazodone Hcl	88	31
Albuterol Sulfate Hfa	Albuterol Sulfate	79	37
Eliquis	Apixaban	79	22
Famotidine	Famotidine	78	18
Simvastatin	Simvastatin	78	33
Ozempic	Semaglutide	75	17
Tamsulosin Hcl	Tamsulosin Hcl	74	21
Alendronate Sodium	Alendronate Sodium	66	22
Metformin Hcl Er	Metformin Hcl	57	22
Carvedilol	Carvedilol	55	19
Pravastatin Sodium	Pravastatin Sodium	54	21
Clopidogrel	Clopidogrel Bisulfate	52	19
Clonidine Hcl	Clonidine Hcl	47	13
Citalopram Hbr	Citalopram Hydrobromide	46	15
Jardiance	Empagliflozin	45	17
Bupropion Xl	Bupropion Hcl	44	15
Alprazolam	Alprazolam	42	16
Ibuprofen	Ibuprofen	42	17
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	41	18
Hydralazine Hcl	Hydralazine Hcl	39	15
Atenolol	Atenolol	37	15
Lovastatin	Lovastatin	37	14
Fluoxetine Hcl	Fluoxetine Hcl	36	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	35	13
Ezetimibe	Ezetimibe	34	suppressed
Ibandronate Sodium	Ibandronate Sodium	34	11
Irbesartan	Irbesartan	34	suppressed
Baclofen	Baclofen	32	11
Meloxicam	Meloxicam	32	12
Hydroxyzine Hcl	Hydroxyzine Hcl	30	11
Sumatriptan Succinate	Sumatriptan Succinate	30	suppressed
Duloxetine Hcl	Duloxetine Hcl	29	13
Lactulose	Lactulose	29	suppressed
Buspirone Hcl	Buspirone Hcl	28	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	28	suppressed
Mirtazapine	Mirtazapine	28	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	28	15
Valsartan	Valsartan	26	13
Glimepiride	Glimepiride	25	11
Glipizide	Glipizide	25	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	25	12
Naproxen	Naproxen	25	suppressed
Paroxetine Hcl	Paroxetine Hcl	25	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	25	14
Venlafaxine Hcl Er	Venlafaxine Hcl	25	suppressed
Allopurinol	Allopurinol	24	suppressed
Olanzapine	Olanzapine	24	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	24	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	23	suppressed
Spironolactone	Spironolactone	23	11
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	23	suppressed
Estradiol	Estradiol	22	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	22	suppressed
Valacyclovir	Valacyclovir Hcl	22	suppressed
Diclofenac Sodium	Diclofenac Sodium	21	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	21	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	20	11
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	20	16
Topiramate	Topiramate	20	suppressed
Tramadol Hcl	Tramadol Hcl	20	suppressed
Warfarin Sodium	Warfarin Sodium	20	suppressed
Benazepril Hcl	Benazepril Hcl	18	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	18	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Midodrine Hcl	Midodrine Hcl	17	suppressed
Myrbetriq	Mirabegron	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Celecoxib	Celecoxib	16	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Januvia	Sitagliptin Phosphate	16	suppressed
Synthroid	Levothyroxine Sodium	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	15	suppressed
Prednisone	Prednisone	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Humalog Kwikpen U-100	Insulin Lispro	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	11
Xarelto	Rivaroxaban	14	suppressed
Acyclovir	Acyclovir	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	11
Diazepam	Diazepam	13	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	13	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Rybelsus	Semaglutide	13	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Klor-Con M20	Potassium Chloride	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Temazepam	Temazepam	12	suppressed
Carbamazepine	Carbamazepine	11	suppressed
Gemfibrozil	Gemfibrozil	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	11	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error